Endocrinology Today—May 26, 2026

This week’s Endocrinology update highlights regulatory progress, reimbursement expansion, diabetes technology advances, and emerging cell-based innovation.

In Today’s Newsletter

Dive deeper

💧 Thyconvi approved in Canada [1] [Canada • 19 May 2026]

https://www.biospace.com/press-releases/biosyent-announces-health-canada-approval-of-thyconvi-levothyroxine-oral-solution
Context: Thyconvi (BioSyent; levothyroxine oral solution) contains 20 mcg/mL levothyroxine sodium and does not require refrigeration.
Key point: Health Canada approved Thyconvi for hypothyroidism management and TSH suppression.
Implication: Regulatory approval may expand formulation choice and access for patients needing dose flexibility.

📈 Sogroya gains Korea reimbursement [2] [Korea • 22 May 2026]

https://www.koreabiomed.com/news/articleView.html?idxno=31762
Context: Sogroya (Novo Nordisk; somapacitan) is a once-weekly growth hormone therapy for children and adults with growth hormone deficiency.
Key point: Novo Nordisk Pharma Korea said Sogroya received national health insurance reimbursement in Korea.
Implication: Access support may reduce treatment burden and support adherence in long-term growth hormone therapy.

💊 Alembic levothyroxine tablets get USFDA approval [3] [US • 22 May 2026]

https://www.business-standard.com/amp/markets/capital-market-news/alembic-pharmaceuticals-receives-usfda-approval-for-levothyroxine-sodium-tablets-126052200496_1.html
Context: Alembic’s levothyroxine sodium tablets cover multiple strengths and reference AbbVie’s Synthroid.
Key point: USFDA granted final approval for Alembic’s ANDA for levothyroxine sodium tablets.
Implication: Introduces competition that may affect pricing and formulary access.

🧬 Kerendia T1D CKD sNDA gets FDA Priority Review [4] [US • 21 May 2026]

https://www.businesswire.com/news/home/20260520429132/en/Bayers-KERENDIA-finerenone-Granted-Priority-Review-of-Supplemental-New-Drug-Application-by-U.S.-FDA-for-Treatment-of-Adults-with-Type-1-Diabetes-and-Chronic-Kidney-Disease
Context: FINE-ONE enrolled 242 adults with type 1 diabetes and CKD and evaluated finerenone added to standard of care over six months.
Key point: FDA accepted Bayer’s sNDA and granted Priority Review for Kerendia in adults with type 1 diabetes and CKD.
Implication: May influence prescriber choice and payer reviews pending full data.

📱 Dexcom Flex CGM announced for Germany [5] [Germany • 18 May 2026]

https://www.businesswire.com/news/home/20260518266091/en/Redefining-CGM-for-People-With-Type-2-Diabetes-Dexcom-Announces-Dexcom-Flex-in-Germany
Context: Dexcom Flex is designed for adults with type 2 diabetes using basal insulin, oral therapies, or GLP-1 receptor agonists.
Key point: Dexcom announced the CGM system will be available in Germany soon.
Implication: May expand screening, initiation, and follow-up at scale.

🌙 Lilly tirzepatide Ramadan study reaches completed status [6] [23 May 2026]

https://www.theglobeandmail.com/investing/markets/stocks/LLY/pressreleases/2103275/lillys-tirzepatide-ramadan-study-nears-data-phase-eyeing-a-key-diabetes-market-segment/
Context: The Phase 4, open-label, single-arm study evaluated tirzepatide once weekly in adults with type 2 diabetes during Ramadan fasting.
Key point: The study was marked completed, with Eli Lilly records updated on 20 May 2026.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.

🧫 Stem cell beta-cell trials show early insulin-production promise [7] [23 May 2026]

https://www.sciencealert.com/stem-cells-can-revive-insulin-production-in-type-1-diabetes-trials-show
Context: The article describes embryonic and induced pluripotent stem cell approaches to generate insulin-producing beta cells.
Key point: Early clinical trials suggest transplanted stem cell-derived beta cells can survive, mature, and produce insulin in type 1 diabetes.
Implication: Signals pipeline investment and modality expansion.

🌬️ ANU Ketowhistle breath test moves toward pilot clinical study [8] [Australia • 25 May 2026]

https://science.anu.edu.au/news-events/news/life-changing-nanotechnology-makes-diabetes-care-breeze
Context: Ketowhistle (ANU; nanowire breath sensor) is being developed to detect exhaled ketones linked to diabetic ketoacidosis.
Key point: ANU described an imminent pilot clinical study and commercialisation work through Ketone Innovation.
Implication: May expand screening, initiation, and follow-up at scale.

Why It Matters

Levothyroxine access is expanding through both a new Canadian oral solution and a US generic tablet approval.
Long-acting endocrine therapies, including Sogroya, continue to target adherence barriers in chronic care.
Kerendia’s T1D CKD review could broaden a cardio-kidney drug beyond its current type 2 diabetes CKD use.
Diabetes technology is widening from intensive insulin users to broader type 2 diabetes and non-invasive monitoring settings.
Cell therapy remains experimental, but early beta-cell trial signals keep regenerative diabetes care in focus.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Endocrinology archive on our research hub page.

FAQ

What is Thyconvi (BioSyent)?

Thyconvi is a levothyroxine oral solution approved by Health Canada for hypothyroidism and TSH suppression. BioSyent said it is the first and only levothyroxine oral solution available in Canada. [1]

What changed for Sogroya (Novo Nordisk) in Korea?

Sogroya received national health insurance reimbursement in Korea for children and adults with growth hormone deficiency. It is dosed once weekly. [2]

What did the FDA approve for Alembic?

USFDA granted final ANDA approval for Alembic’s levothyroxine sodium tablets across listed strengths. The product is described as therapeutically equivalent to AbbVie’s Synthroid. [3]

What is the Kerendia regulatory update?

FDA accepted Bayer’s supplemental New Drug Application and granted Priority Review for Kerendia in adults with type 1 diabetes and CKD. The filing is supported by FINE-ONE and pooled Phase 3 data. [4]

Who is Dexcom Flex for?

Dexcom Flex is designed for adults with type 2 diabetes who are not using intensive insulin therapy, including people using basal insulin, oral therapies, or GLP-1 receptor agonists. [5]

Are stem cell beta-cell therapies approved for type 1 diabetes?

The supplied article says these therapies remain experimental and are not yet approved by Health Canada or the US FDA. Patients are advised to consult healthcare professionals before joining approved clinical trials. [7]

Entities / Keywords

BioSyent, Thyconvi, levothyroxine oral solution, hypothyroidism, TSH suppression, Health Canada
Novo Nordisk, Sogroya, somapacitan, growth hormone deficiency, Korea reimbursement
Alembic Pharmaceuticals, levothyroxine sodium tablets, ANDA, USFDA, Synthroid, AbbVie
Bayer, Kerendia, finerenone, FINE-ONE, type 1 diabetes, chronic kidney disease, Priority Review
Dexcom, Dexcom Flex, continuous glucose monitoring, CGM, type 2 diabetes, Germany
Eli Lilly, tirzepatide, Ramadan fasting, Phase 4, type 2 diabetes
Vertex Pharmaceuticals, stem cell-derived beta cells, induced pluripotent stem cells, type 1 diabetes
ANU, Professor Lan Fu, Ketowhistle, Ketone Innovation, diabetic ketoacidosis, breath ketone testing